These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9804127)

  • 1. Mutation involving cytochrome P450IID6 in two Japanese patients with neuroleptic malignant syndrome.
    Kawanishi C; Shimoda Y; Fujimaki J; Onishi H; Suzuki K; Hanihara T; Sugiyama N; Kosaka K
    J Neurol Sci; 1998 Sep; 160(1):102-4. PubMed ID: 9804127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
    Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.
    Kawanishi C; Furuno T; Onishi H; Sugiyama N; Suzuki K; Matsumura T; Ishigami T; Kosaka K
    Psychiatr Genet; 2000 Sep; 10(3):145-7. PubMed ID: 11204351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
    Kato D; Kawanishi C; Kishida I; Furuno T; Suzuki K; Onishi H; Hirayasu Y
    Eur J Clin Pharmacol; 2007 Nov; 63(11):991-6. PubMed ID: 17701031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.
    Kato D; Kawanishi C; Kishida I; Furuno T; Matsumura T; Hasegawa H; Suzuki K; Hirayasu Y
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):504-7. PubMed ID: 16048458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 HhaI genotype and the neuroleptic malignant syndrome.
    Iwahashi K; Yoshihara E; Nakamura K; Ameno K; Watanabe M; Tsuneoka Y; Ichikawa Y; Igarashi K
    Neuropsychobiology; 1999; 39(1):33-7. PubMed ID: 9892857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.
    Ochi S; Kawasoe K; Abe M; Fukuhara R; Sonobe K; Kawabe K; Ueno S
    Gen Hosp Psychiatry; 2011; 33(6):640.e1-2. PubMed ID: 21749835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 Hhal genotype and the neuroleptic malignant syndrome (NMS).
    Iwahashi K; Nakamura K; Suwaki H; Tsuneoka Y; Ichikawa Y
    Clin Chim Acta; 1997 Sep; 265(1):143-4. PubMed ID: 9352138
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.
    Butwicka A; Krystyna S; Retka W; Wolańczyk T
    Eur J Pediatr; 2014 Dec; 173(12):1639-42. PubMed ID: 24253372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome P-450 2D6 gene polymorphism is not associated with neuroleptic malignant syndrome.
    Ueno S; Otani K; Kaneko S; Koshiro K; Kondoh K; Kotani Y; Sano A
    Biol Psychiatry; 1996 Jul; 40(1):72-4. PubMed ID: 8780858
    [No Abstract]   [Full Text] [Related]  

  • 12. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score.
    Ellingrod VL; Schultz SK; Arndt S
    Psychiatr Genet; 2000 Mar; 10(1):9-11. PubMed ID: 10909122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic malignant syndrome in a patient with succinic semialdehyde dehydrogenase deficiency.
    Neu P; Seyfert S; Brockmöller J; Dettling M; Marx P
    Pharmacopsychiatry; 2002 Jan; 35(1):26-8. PubMed ID: 11819156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
    Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
    Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy.
    Kawanishi C
    Am J Pharmacogenomics; 2003; 3(2):89-95. PubMed ID: 12749726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 genotyping in patients on psychoactive drug therapy.
    Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
    Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Risperidone intoxication in a patient with a genetic predisposition as "poor [non]metabolizer"].
    Strauss M; Heinritz W; Hegerl U; Kopf A
    Psychiatr Prax; 2010 May; 37(4):199-201. PubMed ID: 20225176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the predisposition to neuroleptic malignant syndrome genetically transmitted?
    Otani K; Horiuchi M; Kondo T; Kaneko S; Fukushima Y
    Br J Psychiatry; 1991 Jun; 158():850-3. PubMed ID: 1678666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMS and genetic drug oxidation.
    Otani K; Kaneko S; Fukushima Y; Chiba K; Ishizaki T
    Br J Psychiatry; 1991 Oct; 159():595-6. PubMed ID: 1751888
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome.
    Suzuki A; Kondo T; Otani K; Mihara K; Yasui-Furukori N; Sano A; Koshiro K; Kaneko S
    Am J Psychiatry; 2001 Oct; 158(10):1714-6. PubMed ID: 11579007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.